Aethon Therapeutics

CEO, Rajesh Chopra, and Exec. Dir of Proteomics, Lauren Stopfer, are attending the NewYorkBIO Innovation Summit 2024 today as panelists in the session titled, "Growth opportunities and challenges for life science companies in New York." Should be a great discussion! https://lnkd.in/e5KsYirr

It has come to our attention scammers are impersonating our company for false employment opportunities. Stay vigilant, job seekers! Here is a helpful resource on what to look out for: https://lnkd.in/dgkrq6cz

NEW PUBLICATION! HapImmune Platform co-inventor (and now Aethon Therapeutics employee), Lorenzo Maso and team, describes the "molecular basis for antibody recognition of multiple drug-peptide/MHC complexes" in this new PNAS publication: https://lnkd.in/e_qRxBGD This manuscript is full of structure-based insights relevant to haptenated pMHCs, bispecific T-cell engagers, and antibody engineering. Congrats to the team from New York University on this impressive new publication.

Aethon’s unique platform and approach is featured in the latest Genetic Engineering & Biotechnology News – check it out!   Multispecific Antibodies Come to Grips with Manifold Targets (genengnews.com) https://lnkd.in/eeZ3N252

What a past week for Aethon—an earthquake on April 5th and a solar eclipse on April 8th! We love capturing the little and big moments at Aethon Therapeutics on our Polaroid camera 📸

We are excited to announce our collaboration with Revolution Medicines to create novel bispecific antibodies directed towards cancer neoantigens generated by Revolution Medicines’ RAS(ON) inhibitors. https://lnkd.in/eSRG3YYs

We’re #hiring! Aethon is looking to hire a skilled candidate in the field of protein engineering to support our antibody discovery and engineering efforts. This is a great opportunity to work in a fast paced, dynamic, startup environment in New York City! Please apply or share to your network!  #startup #biotech #antibodydiscovery

We are delighted to announce Christoph Rader, CTO at Aethon Therapeutics, will be speaking at the 4th Edition of The Antibody Series (Sept 4 - 6, 2024) on "Creating and targeting synthetic neoepitopes on cancer cells". 💡 Discover Christoph Rader's biography and abstract here: https://lnkd.in/euJzgCyc 🎫 Pre-register free for on-demand access to this talk and more: https://lnkd.in/eNd2cBKp 🌎 THE ANTIBODY SERIES (TAS) is the fastest growing antibody event of its kind. TAS brings together industry and academia experts in-person to exchange innovative ideas in antibody discovery and development co-joined by +4,000 registered antibody members online. #neoepitopes #research #antibody #conference #speaker #tas24

We are #hiring an Office Manager at Aethon Therapeutics to join our growing team in New York City for 2024. We are looking for an organized and adaptable individual, ideally with a background in biology or with previous administrative/management experience in a biotechnology environment. Apply now or share this post with your network!